New hope for stomach cancer patients with low HER2 levels?
NCT ID NCT07529613
First seen Apr 17, 2026 · Last updated May 08, 2026 · Updated 5 times
Summary
This study tested a combination of three drugs—trastuzumab deruxtecan (a targeted therapy), nivolumab (an immunotherapy), and chemotherapy—in 30 people with advanced HER2-low stomach or gastroesophageal junction cancer who had not received prior treatment. The goal was to find the safest dose and see how well the combo shrinks tumors. While promising, this approach aims to control the disease, not cure it, and ongoing treatment is needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Cancer Center Hospital East
Kashiwa, Chiba, 277-8577, Japan
Conditions
Explore the condition pages connected to this study.